Solventum (SOLV) Q3 2024 earnings summary

Executive summary

• Q3 2024 net sales reached $2.082 billion, up 0.4% year-over-year, with organic growth of 0.3% and positive top-line momentum.

• Adjusted EPS was $1.64, while GAAP EPS was $0.70; free cash flow for Q3 was $76 million.

• Raised full-year 2024 guidance for organic sales growth, adjusted EPS ($6.50–$6.65), and free cash flow ($750M–$850M).

• Continued business transformation post-spin-off from 3M, with ongoing restructuring, portfolio optimization, and new product launches across all segments.

• Higher standalone and transition costs, including public company stand-up expenses, impacted margins and net income.

Financial highlights

• Q3 2024 net sales: $2.082 billion (up 0.4% year-over-year); nine months: $6.18 billion (up 0.3%).

• Adjusted operating income was $475 million (margin 22.8%); GAAP operating income was $275 million (margin 13.2%).

• Q3 2024 net income: $122 million, down from $460 million in Q3 2023.

• Gross margin was 56% (down from 58% in Q3 2023); adjusted EPS was $1.64; GAAP EPS was $0.70.

• Q3 free cash flow was $76 million; year-to-date free cash flow totaled $713 million.

Outlook and guidance

• Full-year 2024 organic sales growth expected at the upper half of 0% to 1% range.

• Adjusted EPS guidance raised to $6.50–$6.65; free cash flow guidance increased to $750M–$850M.

• Capital expenditures expected at the lower end of $400–$500 million.

• Q4 EPS guidance of $1.22–$1.37 reflects reversal of one-time Q3 benefits, continued investment, and FX headwinds.

• Management anticipates continued headwinds from higher standalone costs and transition expenses through 2024.